Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis
CONCLUSION: Among 25 AIH patients who were treated with immunomodulatory drugs for different reasons, the majority had a fovorable course, relapse was frequent in difficult-to-treat patients who received belimumab, and four with concomitant IBD had insufficient response.PMID:37716078 | DOI:10.1016/j.jaut.2023.103113 (Source: Journal of Autoimmunity)
Source: Journal of Autoimmunity - September 16, 2023 Category: Allergy & Immunology Authors: Benedetta Terziroli Beretta-Piccoli Gustav Buescher George Dalekos Kalliopi Zachou Anja Geerts Nasser Semmo Mirjam Kolev Eleonora De Martin Maciej K Janik Jo ão Madaleno Milica Lalosevic Stojkovic J érôme Dumortier Thomas Vanwolleghem Ida Schregel Silj Source Type: research
Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis
CONCLUSION: Among 25 AIH patients who were treated with immunomodulatory drugs for different reasons, the majority had a fovorable course, relapse was frequent in difficult-to-treat patients who received belimumab, and four with concomitant IBD had insufficient response.PMID:37716078 | DOI:10.1016/j.jaut.2023.103113 (Source: Journal of Autoimmunity)
Source: Journal of Autoimmunity - September 16, 2023 Category: Allergy & Immunology Authors: Benedetta Terziroli Beretta-Piccoli Gustav Buescher George Dalekos Kalliopi Zachou Anja Geerts Nasser Semmo Mirjam Kolev Eleonora De Martin Maciej K Janik Jo ão Madaleno Milica Lalosevic Stojkovic J érôme Dumortier Thomas Vanwolleghem Ida Schregel Silj Source Type: research
Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis
CONCLUSION: Among 25 AIH patients who were treated with immunomodulatory drugs for different reasons, the majority had a fovorable course, relapse was frequent in difficult-to-treat patients who received belimumab, and four with concomitant IBD had insufficient response.PMID:37716078 | DOI:10.1016/j.jaut.2023.103113 (Source: Journal of Autoimmunity)
Source: Journal of Autoimmunity - September 16, 2023 Category: Allergy & Immunology Authors: Benedetta Terziroli Beretta-Piccoli Gustav Buescher George Dalekos Kalliopi Zachou Anja Geerts Nasser Semmo Mirjam Kolev Eleonora De Martin Maciej K Janik Jo ão Madaleno Milica Lalosevic Stojkovic J érôme Dumortier Thomas Vanwolleghem Ida Schregel Silj Source Type: research
Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis
CONCLUSION: Among 25 AIH patients who were treated with immunomodulatory drugs for different reasons, the majority had a fovorable course, relapse was frequent in difficult-to-treat patients who received belimumab, and four with concomitant IBD had insufficient response.PMID:37716078 | DOI:10.1016/j.jaut.2023.103113 (Source: Journal of Autoimmunity)
Source: Journal of Autoimmunity - September 16, 2023 Category: Allergy & Immunology Authors: Benedetta Terziroli Beretta-Piccoli Gustav Buescher George Dalekos Kalliopi Zachou Anja Geerts Nasser Semmo Mirjam Kolev Eleonora De Martin Maciej K Janik Jo ão Madaleno Milica Lalosevic Stojkovic J érôme Dumortier Thomas Vanwolleghem Ida Schregel Silj Source Type: research
Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis
CONCLUSION: Among 25 AIH patients who were treated with immunomodulatory drugs for different reasons, the majority had a fovorable course, relapse was frequent in difficult-to-treat patients who received belimumab, and four with concomitant IBD had insufficient response.PMID:37716078 | DOI:10.1016/j.jaut.2023.103113 (Source: Journal of Autoimmunity)
Source: Journal of Autoimmunity - September 16, 2023 Category: Allergy & Immunology Authors: Benedetta Terziroli Beretta-Piccoli Gustav Buescher George Dalekos Kalliopi Zachou Anja Geerts Nasser Semmo Mirjam Kolev Eleonora De Martin Maciej K Janik Jo ão Madaleno Milica Lalosevic Stojkovic J érôme Dumortier Thomas Vanwolleghem Ida Schregel Silj Source Type: research
Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis
CONCLUSION: Among 25 AIH patients who were treated with immunomodulatory drugs for different reasons, the majority had a fovorable course, relapse was frequent in difficult-to-treat patients who received belimumab, and four with concomitant IBD had insufficient response.PMID:37716078 | DOI:10.1016/j.jaut.2023.103113 (Source: Journal of Autoimmunity)
Source: Journal of Autoimmunity - September 16, 2023 Category: Allergy & Immunology Authors: Benedetta Terziroli Beretta-Piccoli Gustav Buescher George Dalekos Kalliopi Zachou Anja Geerts Nasser Semmo Mirjam Kolev Eleonora De Martin Maciej K Janik Jo ão Madaleno Milica Lalosevic Stojkovic J érôme Dumortier Thomas Vanwolleghem Ida Schregel Silj Source Type: research
Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis
CONCLUSION: Among 25 AIH patients who were treated with immunomodulatory drugs for different reasons, the majority had a fovorable course, relapse was frequent in difficult-to-treat patients who received belimumab, and four with concomitant IBD had insufficient response.PMID:37716078 | DOI:10.1016/j.jaut.2023.103113 (Source: Journal of Autoimmunity)
Source: Journal of Autoimmunity - September 16, 2023 Category: Allergy & Immunology Authors: Benedetta Terziroli Beretta-Piccoli Gustav Buescher George Dalekos Kalliopi Zachou Anja Geerts Nasser Semmo Mirjam Kolev Eleonora De Martin Maciej K Janik Jo ão Madaleno Milica Lalosevic Stojkovic J érôme Dumortier Thomas Vanwolleghem Ida Schregel Silj Source Type: research
Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden
CONCLUSIONS: Bimekizumab was cost-effective against most available treatments for PsA in Sweden, irrespective of prior TNFi exposure.PMID:37712618 | DOI:10.1080/13696998.2023.2259609 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - September 15, 2023 Category: Health Management Authors: Valgerdur Sigurdardottir Anna Engstrom Patric Berling Tor Olofsson Linnea Oldsberg Susannah Sadler Devian Parra Lode Melis Damon Willems Source Type: research
New drugs for the treatment of IBD during conception, pregnancy, and lactation
The management of inflammatory bowel disease requires continuous medical therapy to achieve and maintain disease control. Thus, women can be exposed to different drugs during conception, pregnancy, and lactation with potentially harmful effects on the mother, foetus, or nursing infant. Conventional drugs and anti-tumour necrosis factor (TNF)- α are considered safe and can be maintained throughout all these phases. Emergent, although limited, data support safety of vedolizumab and ustekinumab, with pregnancy, as well as maternal and neonatal outcomes comparable to women unexposed or treated with anti TNF-α drugs. (Source:...
Source: Digestive and Liver Disease - September 15, 2023 Category: Gastroenterology Authors: Daniela Pugliese, Giuseppe Privitera, Javier P. Gisbert, Mar ía Chaparro Tags: Review Article Source Type: research
Real-world treatment persistence of four commonly prescribed biologic therapies for moderate to severe psoriasis in Australia
CONCLUSIONS: The nationally representative PBS dataset can provide real-world insights into the persistence on biologic therapies for psoriasis in Australia, where eligibility criteria for reimbursed treatment are stringent. Persistence is an indirect marker of sustained treatment effectiveness and tolerability. Both unadjusted and adjusted analyses found longer persistence for guselkumab compared to adalimumab, secukinumab or ustekinumab.PMID:37705180 | DOI:10.1111/ajd.14153 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - September 14, 2023 Category: Dermatology Authors: John Sullivan Sarah Hannam Andrea Puig Debra Maranta Andrew B McGeachie Christopher Baker Source Type: research
Real-world treatment persistence of four commonly prescribed biologic therapies for moderate to severe psoriasis in Australia
CONCLUSIONS: The nationally representative PBS dataset can provide real-world insights into the persistence on biologic therapies for psoriasis in Australia, where eligibility criteria for reimbursed treatment are stringent. Persistence is an indirect marker of sustained treatment effectiveness and tolerability. Both unadjusted and adjusted analyses found longer persistence for guselkumab compared to adalimumab, secukinumab or ustekinumab.PMID:37705180 | DOI:10.1111/ajd.14153 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - September 14, 2023 Category: Dermatology Authors: John Sullivan Sarah Hannam Andrea Puig Debra Maranta Andrew B McGeachie Christopher Baker Source Type: research
Real-world treatment persistence of four commonly prescribed biologic therapies for moderate to severe psoriasis in Australia
CONCLUSIONS: The nationally representative PBS dataset can provide real-world insights into the persistence on biologic therapies for psoriasis in Australia, where eligibility criteria for reimbursed treatment are stringent. Persistence is an indirect marker of sustained treatment effectiveness and tolerability. Both unadjusted and adjusted analyses found longer persistence for guselkumab compared to adalimumab, secukinumab or ustekinumab.PMID:37705180 | DOI:10.1111/ajd.14153 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - September 14, 2023 Category: Dermatology Authors: John Sullivan Sarah Hannam Andrea Puig Debra Maranta Andrew B McGeachie Christopher Baker Source Type: research
